These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

221 related items for PubMed ID: 12094010

  • 21. Cyclooxygenase-2 inhibition attenuates lipopolysaccharide-induced cardiovascular failure.
    Höcherl K, Dreher F, Kurtz A, Bucher M.
    Hypertension; 2002 Dec; 40(6):947-53. PubMed ID: 12468584
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Cyclooxygenase-2 blockade does not impair endothelial vasodilator function in healthy volunteers: randomized evaluation of rofecoxib versus naproxen on endothelium-dependent vasodilatation.
    Verma S, Raj SR, Shewchuk L, Mather KJ, Anderson TJ.
    Circulation; 2001 Dec 11; 104(24):2879-82. PubMed ID: 11739299
    [Abstract] [Full Text] [Related]

  • 25. Inhibition of both COX-1 and COX-2 is required for development of gastric damage in response to nonsteroidal antiinflammatory drugs.
    Tanaka A, Araki H, Komoike Y, Hase S, Takeuchi K.
    J Physiol Paris; 2001 Dec 11; 95(1-6):21-7. PubMed ID: 11595414
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Synthesis, characterization, and activity of metabolites derived from the cyclooxygenase-2 inhibitor rofecoxib (MK-0966, Vioxx).
    Nicoll-Griffith DA, Yergey JA, Trimble LA, Silva JM, Li C, Chauret N, Gauthier JY, Grimm E, Léger S, Roy P, Thérien M, Wang Z, Prasit P, Zamboni R, Young RN, Brideau C, Chan CC, Mancini J, Riendeau D.
    Bioorg Med Chem Lett; 2000 Dec 04; 10(23):2683-6. PubMed ID: 11128651
    [Abstract] [Full Text] [Related]

  • 30. Classic NSAID and selective cyclooxygenase (COX)-1 and COX-2 inhibitors in healing of chronic gastric ulcers.
    Brzozowski T, Konturek PC, Konturek SJ, Sliwowski Z, Pajdo R, Drozdowicz D, Ptak A, Hahn EG.
    Microsc Res Tech; 2001 Jun 01; 53(5):343-53. PubMed ID: 11376495
    [Abstract] [Full Text] [Related]

  • 31. Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model.
    Ehrich EW, Dallob A, De Lepeleire I, Van Hecken A, Riendeau D, Yuan W, Porras A, Wittreich J, Seibold JR, De Schepper P, Mehlisch DR, Gertz BJ.
    Clin Pharmacol Ther; 1999 Mar 01; 65(3):336-47. PubMed ID: 10096266
    [Abstract] [Full Text] [Related]

  • 32. Inhibition of cyclooxygenase-2 attenuates urinary prostanoid excretion without affecting renal renin expression.
    Kammerl MC, Nüsing RM, Seyberth HW, Riegger GA, Kurtz A, Krämer BK.
    Pflugers Arch; 2001 Sep 01; 442(6):842-7. PubMed ID: 11680616
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Selective inhibitors of cyclo-oxygenase-2 (COX-2) induce hypoalgesia in a rat paw model of inflammation.
    Francischi JN, Chaves CT, Moura AC, Lima AS, Rocha OA, Ferreira-Alves DL, Bakhle YS.
    Br J Pharmacol; 2002 Nov 01; 137(6):837-44. PubMed ID: 12411415
    [Abstract] [Full Text] [Related]

  • 36. Inhibition of cyclooxygenase-2 by rofecoxib attenuates the growth and metastatic potential of colorectal carcinoma in mice.
    Yao M, Kargman S, Lam EC, Kelly CR, Zheng Y, Luk P, Kwong E, Evans JF, Wolfe MM.
    Cancer Res; 2003 Feb 01; 63(3):586-92. PubMed ID: 12566300
    [Abstract] [Full Text] [Related]

  • 37. Enhancement of antinociception by co-administration of an opioid drug (morphine) and a preferential cyclooxygenase-2 inhibitor (rofecoxib) in rats.
    Déciga-Campos M, López UG, Reval MI, López-Muñoz FJ.
    Eur J Pharmacol; 2003 Jan 24; 460(2-3):99-107. PubMed ID: 12559369
    [Abstract] [Full Text] [Related]

  • 38. Role of cyclooxygenase (COX)-1 and COX-2 inhibition in nonsteroidal anti-inflammatory drug-induced intestinal damage in rats: relation to various pathogenic events.
    Tanaka A, Hase S, Miyazawa T, Ohno R, Takeuchi K.
    J Pharmacol Exp Ther; 2002 Dec 24; 303(3):1248-54. PubMed ID: 12438549
    [Abstract] [Full Text] [Related]

  • 39. The selective cyclooxygenase-2 inhibitor rofecoxib reduces kainate-induced cell death in the rat hippocampus.
    Kunz T, Oliw EH.
    Eur J Neurosci; 2001 Feb 24; 13(3):569-75. PubMed ID: 11168565
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.